167 related articles for article (PubMed ID: 25444512)
1. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O
Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512
[TBL] [Abstract][Full Text] [Related]
2. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
[TBL] [Abstract][Full Text] [Related]
3. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
Tomimaru Y; Eguchi H; Satoh T; Tomokuni A; Asaoka T; Wada H; Marubashi S; Ogawa K; Takehara T; Mori M; Doki Y; Nagano H
Jpn J Clin Oncol; 2015 Apr; 45(4):343-8. PubMed ID: 25589454
[TBL] [Abstract][Full Text] [Related]
5. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Takahashi H; Ohigashi H; Gotoh K; Marubashi S; Yamada T; Murata M; Ioka T; Uehara H; Yano M; Ishikawa O
Ann Surg; 2013 Dec; 258(6):1040-50. PubMed ID: 23799421
[TBL] [Abstract][Full Text] [Related]
6. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Takahashi H; Ohigashi H; Ishikawa O; Gotoh K; Yamada T; Nagata S; Tomita Y; Eguchi H; Doki Y; Yano M
Ann Surg; 2012 Jan; 255(1):95-102. PubMed ID: 22123160
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
[TBL] [Abstract][Full Text] [Related]
8. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Akita H; Wada H; Tomokuni A; Asukai K; Takahashi Y; Yanagimoto Y; Matsunaga T; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Yamamoto T; Nakanishi M; Shirayanagi M; Yamasaki T; Ohue M; Yano M; Sakon M; Ishikawa O
Surgery; 2018 Dec; 164(6):1168-1177. PubMed ID: 30146098
[TBL] [Abstract][Full Text] [Related]
9. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
[TBL] [Abstract][Full Text] [Related]
13. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
17. Significance of Simultaneous Splenic Artery Resection in Left-Sided Portal Hypertension After Pancreaticoduodenectomy with Combined Portal Vein Resection.
Gyoten K; Mizuno S; Nagata M; Ogura T; Usui M; Isaji S
World J Surg; 2017 Aug; 41(8):2111-2120. PubMed ID: 28258459
[TBL] [Abstract][Full Text] [Related]
18. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
Hong TS; Ryan DP; Borger DR; Blaszkowsky LS; Yeap BY; Ancukiewicz M; Deshpande V; Shinagare S; Wo JY; Boucher Y; Wadlow RC; Kwak EL; Allen JN; Clark JW; Zhu AX; Ferrone CR; Mamon HJ; Adams J; Winrich B; Grillo T; Jain RK; DeLaney TF; Fernandez-del Castillo C; Duda DG
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):830-8. PubMed ID: 24867540
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
